Skip to content
Hexylcaine
Cyclaine (hexylcaine) is a small molecule pharmaceutical. Hexylcaine was first approved as Cyclaine on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hexylcaine hydrochloride
Tradename
Company
Number
Date
Products
CYCLAINEMerck KGaAN-008472 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHEXYLCAINE
INNhexylcaine
Description
Hexylcaine hydrochloride, also called cyclaine (Merck) or osmocaine, is a short-acting local anesthetic. It acts by inhibiting sodium channel conduction. Overdose can lead to headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.
Classification
Small molecule
Drug classlocal anesthetics
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(CNC1CCCCC1)OC(=O)c1ccccc1
Identifiers
PDB—
CAS-ID532-77-4
RxCUI26879
ChEMBL IDCHEMBL1197
ChEBI ID34791
PubChem CID10770
DrugBankDB00473
UNII ID511IU0826Z (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 45 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details